+186.7%
NFLX vs MRNA
+521.0%
-334.3%
-75.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | 0.0% | +0.7% | -0.8% | -0.1% |
| 7D | -8.1% | -8.2% | +0.2% | -7.6% |
| 30D | +1.6% | +125.6% | -123.9% | -7.1% |
| 3M | -7.3% | +197.1% | -204.4% | -17.4% |
| 6M | -21.6% | +148.5% | -170.1% | -29.3% |
| YTD | -18.9% | +363.3% | -382.2% | -31.1% |
| 1Y | -39.1% | +462.0% | -501.1% | -49.4% |
| 3Y | +71.7% | +26.9% | +44.7% | +57.3% |
| 5Y | +27.0% | -69.6% | +96.6% | +22.8% |
| All | +186.7% | +521.0% | -334.3% | +129.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling